Founded Year

2013

Stage

Series C | Alive

Total Raised

$34.62M

Last Raised

$8.4M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-7 points in the past 30 days

About Techcyte

Techcyte focuses on aiding in the practice of pathology with its artificial intelligence (AI) software platform in the clinical pathology sector. It offers a range of AI-assisted diagnostic tools that improve the efficiency and accuracy of laboratory testing. Techcyte's solutions cater to various applications, including oncology, microbiology, hematology, and infectious disease, as well as industries such as veterinary, environmental, and human healthcare. It was founded in 2013 and is based in Orem, Utah.

Headquarters Location

1106 North 1200 West Suite 202

Orem, Utah, 84057,

United States

888-878-3249

Loading...

ESPs containing Techcyte

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The digital pathology for general diagnostics market refers to the use of digital imaging technology and computational tools to analyze and interpret pathology specimens for diagnostic purposes. Instead of using traditional glass slides, digital pathology involves digitizing tissue samples and creating high-resolution images that can be viewed and analyzed on computer screens. These digital images…

Techcyte named as Outperformer among 15 other companies, including Philips, Proscia, and Ibex.

Techcyte's Products & Differentiators

    Techcyte Fusion CP

    SAAS-based AI and workflow platform for diagnosing clinical pathology samples. Solution suites for cervical cytology, hematology, parasitology, and bacteriology are available on the platform.

Loading...

Research containing Techcyte

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Techcyte in 3 CB Insights research briefs, most recently on Jul 15, 2024.

Expert Collections containing Techcyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Techcyte is included in 3 Expert Collections, including Digital Health.

D

Digital Health

12,122 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

O

Oncology Tech

571 items

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.

A

Artificial Intelligence (AI)

20,628 items

Techcyte Patents

Techcyte has filed 10 patents.

The 3 most popular patent topics include:

  • hematology
  • immunologic tests
  • microscopy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/17/2020

5/28/2024

Microscopy, Microscopes, Cell imaging, Mass spectrometry, Staining

Grant

Application Date

1/17/2020

Grant Date

5/28/2024

Title

Related Topics

Microscopy, Microscopes, Cell imaging, Mass spectrometry, Staining

Status

Grant

Latest Techcyte News

AI Outperforms Traditional Methods for Detecting Parasites in Stool Samples

Oct 23, 2025

“It has been a groundbreaking effort, and what we’ve accomplished is remarkable,” said lead author  Blaine Mathison , ARUP’s technical director of parasitology and an adjunct lecturer in the University of Utah’s Department of Pathology. “Our validation studies have demonstrated the AI algorithm has better clinical sensitivity, improving the likelihood that a pathogenic parasite may be detected.” A leading national reference lab,  ARUP  is an independent nonprofit enterprise of the University of Utah and the School of Medicine’s  Department of Pathology , where Mathison is an adjunct instructor. Training the AI on thousands of samples To build and test the system, ARUP and its partner, a Utah tech firm called  Techcyte , trained the AI using more than 4,000 parasite-positive samples collected from laboratories across the United States, Europe, Africa and Asia. These samples represented 27 classes of parasites, including rare species, such as Schistosoma japonicum and Paracapillaria philippinensis from the Philippines, and Schistosoma mansoni from Africa. “This was really a robust study when you consider the number of organisms and positive specimens used to validate the AI algorithm,” Mathison said. After discrepancy analysis, the positive agreement between AI and manual review was 98.6%. The tool also picked up 169 additional organisms that had been missed in earlier manual reviews. “We are identifying more organisms than we would without the AI, which improves diagnosis and treatment for patients who are affected,” said Adam Barker, ARUP’s chief operations officer. Furthermore, a limit of detection study found AI consistently found more parasites than the technologists did, even when the samples were highly diluted, suggesting the system can detect infections at earlier stages or when parasite levels are low. From innovation to implementation ARUP has pioneered the use of AI in clinical parasitology for years. In 2019, it became the world’s first lab to apply AI to the trichrome portion of the ova and parasite test. In March 2025, it expanded that capability to include the wet-mount analysis—becoming the first laboratory to use AI for the entire testing process. That timing proved propitious: in August, ARUP received a record number of specimens for parasite testing. The efficiency gained through AI enabled the lab to meet demand without compromising quality. “An AI algorithm is only as good as the personnel inputting the data,” Barker said. “We have phenomenal staff who have used their extensive knowledge and skills to build an exceptional AI solution that benefits not just the laboratory, but also patients.” ARUP and Techcyte plan to continue expanding AI’s role in diagnostic testing. Beyond parasitology, ARUP has already implemented AI to assist with Pap testing and is developing other tools to streamline lab operations and improve diagnostic accuracy. Reference: Mathison Blaine A., Knight Katie, Potts Jill, et al. Detection of protozoan and helminth parasites in concentrated wet mounts of stool using a deep convolutional neural network. J Clin Microbiol. 2025:e01062-25. doi: 10.1128/jcm.01062-25 This article has been republished from the following materials . Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here . Advertisement

Techcyte Frequently Asked Questions (FAQ)

  • When was Techcyte founded?

    Techcyte was founded in 2013.

  • Where is Techcyte's headquarters?

    Techcyte's headquarters is located at 1106 North 1200 West, Orem.

  • What is Techcyte's latest funding round?

    Techcyte's latest funding round is Series C.

  • How much did Techcyte raise?

    Techcyte raised a total of $34.62M.

  • Who are the investors of Techcyte?

    Investors of Techcyte include Alta Ventures Mexico, Zoetis, ARUP Laboratories, Paycheck Protection Program, The University of Utah and 3 more.

  • Who are Techcyte's competitors?

    Competitors of Techcyte include Hologic and 4 more.

  • What products does Techcyte offer?

    Techcyte's products include Techcyte Fusion CP and 4 more.

Loading...

Compare Techcyte to Competitors

4D Path Logo
4D Path

4D Path is a company that operates within the healthcare industry. They have developed a platform that measures and quantifies cell cycle deregulations and tumor microenvironment dynamics to predict patient responses to cancer therapies. Their technology provides biomarker profiling and stratification from histopathology images. It was founded in 2016 and is based in Newton Center, Massachusetts.

M
Mechanomind

Mechanomind provides AI diagnostics for skin cancer within the healthcare technology sector. The company utilizes computer vision and deep learning to assist in the diagnosis of skin cancer, including the classification of skin tumor subtypes and offering decision support for pathologists. Mechanomind's technology is scanner and image quality agnostic, aimed at maintaining accuracy and efficiency in histopathology analysis. It was founded in 2015 and is based in New York, New York.

TRIBVN Healthcare Logo
TRIBVN Healthcare

TRIBVN Healthcare is a company that provides digital pathology solutions, using artificial intelligence to assist in cancer diagnosis within the healthcare sector. The company has a digital pathology platform that includes image management, AI applications for diagnostics, case sharing, and data archiving solutions, aimed at improving the workflow of pathologists. TRIBVN Healthcare serves diagnostic laboratories and pharmaceutical and biotech companies. It was founded in 2011 and is based in Paris, France.

Qritive Logo
Qritive

Qritive is a company that focuses on AI diagnostics in the healthcare sector, particularly in pathology. They develop AI solutions to assist pathologists in managing workflows from diagnosis to treatment. Their main offerings include a clinical-decision support system for pathologists and an image management platform called Pantheon, which are intended to support cancer diagnoses. It was founded in 2017 and is based in Singapore, Singapore.

Cerba HealthCare Logo
Cerba HealthCare

Cerba HealthCare provides medical diagnostics within the healthcare sector. It offers diagnostic services including proximity biology, specialty biology, clinical trial biology, anatomical and cytological pathology, medical imaging, and preventive biology. These services are used for the diagnosis and management of diseases. It was founded in 1967 and is based in Issy-les-Moulineaux, France.

I
Imagene AI

Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.